A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma - PubMed
2 days ago
- #Biomarker Analysis
- #Mucosal Melanoma
- #Immunotherapy
- Phase II study of neoadjuvant pembrolizumab plus lenvatinib followed by surgery and adjuvant pembrolizumab in resectable mucosal melanoma.
- Primary endpoint (pathological complete response rate) was not met; pCR rate was 9.5%, with a major pathologic response rate of 19.0%, and overall pathologic response rate of 38.1%.
- Median relapse-free survival was 14.8 months; median overall survival was not reached, and treatment was safe with no grade 4-5 toxicities or perioperative complications.
- Spatial profiling showed responders had a more immune-inflamed baseline microenvironment with activated CD4+/CD8+ T cell signatures linked to better outcomes, and treatment induced vascular normalization and increased T cell infiltration in non-responders.